Xience Versus Synergy in Left Main PCI

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 818 participants.

Also called NCT02303717

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 818 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02303717
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02303717. Randomized; single masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Xience Versus Synergy in Left Main PCI
Acronym
IDEAL-LM
Intervention (Drug)
Dual antiplatelet therapy
Lead sponsor
NHS National Waiting Times Centre Board (class: other)
Collaborator
Boston Scientific Corporation (class: industry)
Collaborator
Venn Life Sciences (class: other)
Collaborator
Cardialysis B.V. (class: industry)
Collaborator
Diagram B.V. (class: other)

Record details

Record id
cardio:ct-nct02303717
Content hash
7aec4a17e0dc5b63cdcbc81ff656eeedf374ba55ed383f5ccec7a3c1bf7e0a45